Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396988 | 1.00 | AR (0.43) | ARLRRK2TRPA1MBOAT4NOTUM | |
| SCHEMBL1536118 | 0.87 | AR (0.53) | AR | |
| SCHEMBL30444359 | 0.87 | AR (0.53) | AR | |
| SCHEMBL19564468 | 0.83 | CSNK1A1 (0.38) | ARLRRK2MBOAT4KCNQ3KCNQ2 | |
| SCHEMBL29878757 | 0.79 | AR (0.44) | ARTRPA1MBOAT4 | |
| SCHEMBL19851326 | 0.79 | AR (0.44) | ARLRRK2MBOAT4 | |
| SCHEMBL29878245 | 0.79 | MBOAT4 (0.43) | ARTRPA1MBOAT4 | |
| SCHEMBL19837558 | 0.79 | AR (0.42) | ARLRRK2TRPA1MBOAT4 | |
| SCHEMBL29878229 | 0.79 | AR (0.42) | ARLRRK2TRPA1MBOAT4 | |
| SCHEMBL19837343 | 0.79 | AR (0.39) | ARLRRK2TRPA1MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090792-A1 | AMIDE PRODRUGS AND USES THEREOF | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3494120-B1 | OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-17 | — | — | EP | disclosed |
| US-10308667-B2 | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-04 | — | — | US | disclosed |
| US-9994591-B2 | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9994591-B2 | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | BOEHRINGER INGELHEIM INERNATIONAL GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | BOEHRINGER INGELHEIM INERNATIONAL GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| WO-2018024653-A1 | OXADIAZOLOPYRIDINE DERIVATES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | AR 1071/4885LRRK2 467/4885TRPA1 4835/4885 |
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | MBOAT4, GIPR, ACAT1 | AR 1182/4885LRRK2 3339/4885TRPA1 1442/4885 |
| US-10308667-B2 | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | MBOAT4, MOGAT2, ACAT1 | AR 1151/4885LRRK2 3279/4885TRPA1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.